Form 4: ADC Therapeutics Director Viviane Monges Receives Annual Equity Grant

ADC Therapeutics SA Director Viviane Monges was granted 40,000 common shares as part of her annual equity compensation, vesting in one year.

Summary

• Viviane Monges, a Director of ADC Therapeutics SA (ADCT), acquired 40,000 common shares.
• The acquisition occurred on June 3, 2025, and was reported on June 5, 2025.
• These shares are part of an annual grant of Restricted Stock Units (RSUs) under the Issuer's 2019 Equity Incentive Plan.
• The RSUs were granted for service as a Director and vest one year from the grant date, contingent on continued service.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Viviane Monges beneficially owns 146,627 common shares.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders and indicates continuity. There are no negative surprises or significant risks disclosed beyond standard RSU vesting conditions.

Positives

• The grant of 40,000 Restricted Stock Units (RSUs) to Director Viviane Monges aligns her interests with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• This is a standard form of compensation for directors, indicating continuity in corporate governance practices.

Negatives

• The vesting of these RSUs will result in a minor dilution of existing shares when they convert to common stock.

Risks

• The vesting of the RSUs is subject to the reporting person's continued service to the Issuer, meaning the shares are not immediately owned and could be forfeited if service ceases before vesting.

Future Outlook

The document indicates that the granted Restricted Stock Units will vest one year from the grant date (June 3, 2025), contingent upon the director's continued service, aligning future compensation with ongoing performance.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors like ADC Therapeutics, to attract and retain talent, and align executive and director interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as director compensation is a standard practice in publicly traded companies, particularly within the biotechnology and pharmaceutical industries.
• While the specific number of shares (40,000) and the total beneficial ownership (146,627 shares) are specific to ADC Therapeutics and Viviane Monges, this compensation mechanism is widely adopted by companies such as Biogen Inc., Gilead Sciences, Inc., and Amgen Inc. to incentivize long-term commitment and align director interests with shareholder returns.
• No specific comparable projects or results are detailed in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential future dilution upon vesting of RSUs, but also increased alignment of director's interests with shareholder value.
• Viviane Monges (Director): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The 40,000 Restricted Stock Units are expected to vest on June 3, 2026, subject to Viviane Monges' continued service to ADC Therapeutics SA.

Key Dates

Recommendation

Keywords

ADC Therapeutics, ADCT, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Incentive Plan, Beneficial Ownership